Holocene Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Holocene Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-667,950	Closed	-$68.1M	–	916
2023 Q2	$68.1M	Buy	667,950 +363,225	+119%	+$34.4M	0.29%	109
2023 Q1	$27.7M	Buy	+304,725	New	+$17.9M	0.14%	178

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Holocene Advisors's RETA Position: Q3 2023 in Review

Holocene Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 667,950 shares — an estimated $68.1M sold.

Holocene Advisors first reported a position in RETA in Q1 2023 and held it in 2 quarters. The position peaked at $68.1M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Holocene Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Holocene Advisors sold 667,950 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $68.1M.
Holocene Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 2 quarters.
Holocene Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $68.1M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Holocene Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.